Loading...
Loading...
MRUS| Name | Value |
|---|---|
| Revenues | 7.3M |
| Cost of Revenue | 0.0M |
| Gross Profit | 7.3M |
| Operating Expense | 71.1M |
| Operating I/L | -64.4M |
| Other Income/Expense | 12.4M |
| Interest Income | 7.1M |
| Pretax | -47.7M |
| Income Tax Expense | 2.3M |
| Net Income/Loss | -50.0M |
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands. The company focuses on the discovery and development of bispecific antibody therapeutics. Its pipeline includes Zenocutuzumab (MCLA-128) in phase 2 clinical trials for metastatic breast cancer and phase 1/2 trials for solid tumors with Neuregulin 1. Additionally, it is developing MCLA-158 and MCLA-145 for solid tumors, MCLA-129 for advanced non-small cell lung cancer and other solid tumors, and ONO-4685 for relapsed/refractory T cell lymphoma. Merus N.V. also has collaboration agreements with Betta Pharmaceuticals Co. Ltd and Incyte Corporation for the research and development of bispecific antibody candidates.
